Overview
Portfolio
More
Hemi
Palo Alto, United States
Focuses on partnering with tech‑rebellious entrepreneurs building cutting‑edge innovations that unlock new frontiers for human potential.
Portfolio
20+
Employees
N/A
Founded
2016
AUM
N/A
Investment focus
Stages
No stages listed
Industries
No industries listedGeographic scope
United States
Sources
Hemi
Focuses on partnering with tech‑rebellious entrepreneurs building cutting‑edge innovations that unlock new frontiers for human potential.
Portfolio
20+
Employees
N/A
Founded
2016
AUM
N/A
Stages
No stages listed
Industries
No industries listedGeographic scope
United States
Sources
Showing 15 of 15 matched portfolio companies
Alcatraz provides the Rock X, an edge‑deployed facial biometric authenticator that plugs in‑line with existing Wiegand or OSDP access control systems to replace or augment badge readers. Using AI‑driven 3‑D liveness detection and on‑device matching, it delivers instant, privacy‑by‑design authentication with built‑in tailgating detection, video capture, and SIP intercom support, all managed via a centralized cloud or on‑premise portal.
Funding: $25.0M
Rough estimate of the amount of funding raised
Funding: $25.0M
Rough estimate of the amount of funding raised
BioAesthetics develops biomaterials designed for regenerative medicine applications, focusing on enhancing tissue repair and integration. The company addresses the challenges of biocompatibility and functionality in medical implants, improving patient outcomes and recovery times.
Funding: $6.8M
Rough estimate of the amount of funding raised
Funding: $6.8M
Rough estimate of the amount of funding raised
Airmod is an AI-driven continuous breathing sound monitor that provides real-time, non-invasive assessment of airway patency during procedural sedation. This technology enables early detection of airway obstruction, enhancing patient safety and facilitating timely interventions by medical professionals.
MemryX is developing an Edge AI Accelerator that employs specialized AI chip architecture to improve processing efficiency for edge devices. This technology enables real-time data analysis and decision-making in environments with limited computational resources.
Funding: $19.0M
Rough estimate of the amount of funding raised
Funding: $19.0M
Rough estimate of the amount of funding raised
MetaMe Health develops FDA-cleared prescription digital therapeutics that utilize software applications to train the brain for managing gastrointestinal conditions. This approach provides patients with a non-pharmacological option to alleviate chronic pain and improve their quality of life through accessible mobile technology.
Mythic Therapeutics develops FateControl™ technology to enhance the efficacy of antibody-drug conjugates (ADCs) by increasing their uptake in cancer cells while preventing payload release in healthy tissues. This approach significantly improves treatment outcomes for a wider range of cancer types by reducing toxicity and side effects associated with traditional chemotherapy delivery methods.
Funding: $156.5M
Rough estimate of the amount of funding raised
Funding: $156.5M
Rough estimate of the amount of funding raised
NAVAN Technologies utilizes NanoStraws for non-perturbative delivery of various cargo types into primary cells, enhancing cell viability and function. This technology addresses the manufacturing challenges of vector-based cell and gene therapies, enabling the development of effective treatments across a wide range of medical indications.
Persephone Biosciences utilizes artificial intelligence and synthetic biology to develop microbial-based immunotherapies that restore human microbiomes, addressing the health impacts of damaged ecosystems. Their approach aims to enhance therapeutic responses and improve patient outcomes in the fight against cancer.
Funding: $15.1M
Rough estimate of the amount of funding raised
Funding: $15.1M
Rough estimate of the amount of funding raised
Phase Genomics develops ultra-long-range genome sequencing technology and computational tools that enable the assembly of complete and accurate genomes and metagenomes without the need for cultivation. This platform addresses the challenge of obtaining high-resolution genomic data, facilitating breakthroughs in agriculture, human health, and industrial biology.
Funding: $5.8M
Rough estimate of the amount of funding raised
Funding: $5.8M
Rough estimate of the amount of funding raised
This biotech company develops a platform that utilizes artificial intelligence, computer vision, and high-content screening to analyze tumor stroma in complex disease models. By enabling pharmaceutical companies to identify drug candidates more efficiently, the platform addresses the challenges of drug discovery in oncology.
Point One Navigation provides a centimeter-accurate localization service through its Polaris RTK platform, utilizing a global network of base stations and advanced GNSS technology. This solution addresses the need for precise positioning in applications such as robotics, autonomous vehicles, and precision agriculture, ensuring reliable performance with 99.9% uptime and rapid convergence times.
Funding: $37.4M
Rough estimate of the amount of funding raised
Funding: $37.4M
Rough estimate of the amount of funding raised
The startup has developed an analytic platform that utilizes cell-free DNA to enable early disease detection through a single blood draw. This technology facilitates the rapid development and validation of screening tests for multiple diseases, enhancing diagnostic efficiency for medical professionals.
Tensorflight provides a property intelligence platform that utilizes computer vision and AI to automate property inspections, risk assessment, and underwriting for the insurance industry. By processing near real-time data, the platform enhances risk evaluation accuracy and significantly reduces the time required for claims processing.
Upfort is a cyber security and insurance platform that combines autonomous threat detection with robust cyber insurance to protect businesses from ransomware, data breaches, and wire fraud. The platform offers automated risk assessment and underwriting, enabling organizations to efficiently manage their cyber risk and minimize financial losses from cyber incidents.
Funding: $16.4M
Rough estimate of the amount of funding raised
Funding: $16.4M
Rough estimate of the amount of funding raised
X-37 utilizes AI-driven methodologies to identify and develop small molecules targeting difficult-to-drug proteins associated with autoimmune diseases, cancer, and anticoagulation. By focusing on high-value therapeutic targets, the company aims to accelerate the discovery of safe and effective treatments in areas traditionally resistant to conventional drug development.
<3
100+Approximate amount of employees
Funding: $14.5M
Rough estimate of the amount of funding raised
Funding: $14.5M
Rough estimate of the amount of funding raised
Showing 5 of 5 unmatched portfolio companies